Combination of HBIG and lamivudine-resistant mutations: a formula for trouble?
Fontana
Robert J
RJ
Division of Gastroenterology University of Michigan Medical School Ann Arbor, MI, USA.
Lok
Anna S F
AS
D004259:DNA-Directed DNA Polymerase / Q000235:genetics; D004351:Drug Resistance / Q000235:genetics; D004359:Drug Therapy, Combination; D006509:Hepatitis B / Q000188:drug therapy / Q000821:virology; D006515:Hepatitis B virus / Q000235:genetics / Q000502:physiology*; D006801:Humans; D007136:Immunoglobulins / Q000627:therapeutic use*; D019259:Lamivudine / Q000009:adverse effects* / Q000627:therapeutic use*; D016031:Liver Transplantation; D009154:Mutation / Q000502:physiology*; D011183:Postoperative Complications; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D014779:Virus Replication / Q000187:drug effects
D007136:Immunoglobulins; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; D004259:DNA-Directed DNA Polymerase; C045213:hepatitis B hyperimmune globulin